Fundraising FoxAvalon BioVentures — 2021 Investments
1 investments dated 2021 · listed companies and verified rows first · show all
Jnana has developed RAPID, a next-generation chemoproteomics platform that enables rapid discovery of small molecule drugs targeting previously inaccessible disease targets by identifying novel binding sites on complex proteins.
AI & Machine LearningBiotechDeep TechAustin, US
Joanne Dove Kotz(Founder)inJoel Barrish(Chief Scientific Officer)Donald W. Nicholson(Director)Matthew Hammond(Director)Caroline Stark Beer(Chief Business Officer)Carlo Rizzuto(Director)
Board seatKevin J. Kinsella· per SEC Form D
Co-investorsBain Capital Life SciencesPfizer Venture InvestmentsRA CapitalPfizer VenturesPolaris PartnersVersant Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.